Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
687
datasets available to search
ShareScore release 0.9.0
Dataset results
687 results for “MDS”
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
ClinicalTrials.gov study NCT02469415. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT00569010. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT02014051. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
ClinicalTrials.gov study NCT05282459. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
ClinicalTrials.gov study NCT04582864. IPD Sharing: YES. Countries: 1. Publications: 0.
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00656617. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
ClinicalTrials.gov study NCT01891968. IPD Sharing: Not stated. Countries: 1. Publications: 0.
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
ClinicalTrials.gov study NCT03745716. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
ClinicalTrials.gov study NCT00839982. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
ClinicalTrials.gov study NCT00439673. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
ClinicalTrials.gov study NCT00882102. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
ClinicalTrials.gov study NCT04231851. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
ClinicalTrials.gov study NCT04842604. IPD Sharing: Not stated. Countries: 11. Publications: 0.
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
ClinicalTrials.gov study NCT02907359. IPD Sharing: NO. Countries: 14. Publications: 0.
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
ClinicalTrials.gov study NCT03417154. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT01893372. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
ClinicalTrials.gov study NCT04151706. IPD Sharing: NO. Countries: 1. Publications: 0.
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Req
ClinicalTrials.gov study NCT03900715. IPD Sharing: YES. Countries: 1. Publications: 0.
Bendamustine in Acute Leukemia and MDS
ClinicalTrials.gov study NCT00790855. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Trans
ClinicalTrials.gov study NCT00548847. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.